Documente Academic
Documente Profesional
Documente Cultură
01 Introducere
Structură chimică, clasă terapeutică
02 Farmacologie
Administrare, mod de acțiune, interacțiuni farmacologice, eliminare
03 Utilizare
Indicații terapeutice, contraindicații
04 Particularități
Adresabilitate
01 Introducere
Ce este sulpirida?
Structură chimică, clasă terapeutică
Sulpiridă
Antipsihotic atipic
Benzamidă substituită
Amestec racemic al 2 enantiomeri:
➢ S-sulpiridă (mai potent)
➢ L-sulpiridă
02 Farmacologie
Cum acționează sulpirida?
Administrare, mod de acțiune, interacțiuni farmacologice, metabolizare
Eglonyl – formă farmaceutică
Hiperprolactinemie
Pacienți vârstnici/cu
comorbidități somatice
Tolerabilitate generală bună, nu
se metabolizează hepatic, puține
interacțiuni medicamentoase
Referințe
Ago, Y., Nakamura, S., Baba, A., & Matsuda, T. (2005). Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex.
Neuropsychopharmacology, 30(1), 43–51. https://doi.org/10.1038/sj.npp.1300567
Bell, C., Bhikha, S., Colhoun, H., Carter, F., Frampton, C., & Porter, R. (2013). The response to sulpiride in social anxiety disorder: D2 receptor function. Journal of Psychopharmacology, 27(2), 146–
151. https://doi.org/10.1177/0269881112450778
Caley, C. F., & Weber, S. S. (1995). SULPIRIDE: An antipsychotic with selective dopaminergic antagonist properties.
Herrera-marschitz, M., Stahle, L., Zetterstrom, T., & Ungerstedt, U. (2000). Behavioural and Biochemical Studies With the Benzam ide Sulpiride in Rats.
Lee, H. A., Kim, K. S., Park, S. J., & Kim, E. J. (2009). Cellular mechanism of the QT prolongation induced by sulpiride. International Journal of Toxicology, 28(3), 207–212.
https://doi.org/10.1177/1091581809337261
Mitul A. Mehta, Barbara J., Sahakian Peter J. McKenna, & Trevor W. Robbins. (1999). Systemic sulpiride in young adult volunte ers simulates the profile of cognitive deficits in Parkinson’s disease.
Meyer-Lindenberg, A., Rammsayer, T., Ulferts, J., & Gallhofer, B. (1997). The effects of sulpiride on psychomotor performance an d subjective tolerance. In European Neuropsychopharmacology
(Vol. 7).
Nakazato, T., Horikawa, H. P. M., & Akiyama, A. (1998). The dopamine D receptor antagonist sulpiride causes long-lasting 2 serotonin release. In European Journal of Pharmacology (Vol. 363).
Prospect Eglonyl 50 mg. (n.d.).
Prospect Eglonyl 200 mg. (n.d.).
Rezumatul caracteristicilor produsului Eglonyl 50 mg. (n.d.).
Rezumatul caracteristicilor produsului Eglonyl 200 mg. (n.d.).
Riitherl, E., Degner’, D., Munze12, U., Brunne3, E., Lenhard3, C., Bieh14, /, Vogtle-/, U., & Lenhard, G. (1999). Antidepressant Action of Sulpiride. Results of a Placebo-Controlled Double-Blind Trial.
Rouillon F., & et al. (2001). Sulpiride in the Treatment of Somatoform Disorders: Results of a European Observational Study to Characterize the Responder Profile.
Tsukamoto, T., Asakura, M., Tsuneizumi, T., Satoh, Y., Shinozuka, T., & Hasegawa, K. (1994). Therapeutic effects and side effects in patients with major depression treated with sulpiride once a
day.
Wagstaff, A. J., Fitton, A., Benfield, P., & Bardgett, M. E. (1994). Sulpiride: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Schizophrenia. In eNS
Drugs (Vol. 2, Issue 4).
Vă mulțumesc!
Q&A